Brief: Apexigen Announces New Data From A Phase 1/2 Trial Evaluating Its Cd40 Antibody, Sotigalimab
11/11/2022 13:15
Nov 11 (Reuters) - Apexigen Inc APGN.O :
* APEXIGEN ANNOUNCES NEW DATA FROM A PHASE 1/2 TRIAL
EVALUATING
ITS CD40 ANTIBODY, SOTIGALIMAB, IN COMBINATION WITH
PEMBROLIZUMAB IN PATIENTS WITH FIRST-LINE METASTATIC MELANOMA AT
THE SITC 2022 ANNUAL MEETING
* APEXIGEN INC- COMBINATION OF INTRATUMORAL SOTIGALIMAB AND
SYSTEMIC PEMBROLIZUMAB WAS WELL-TOLERATED
* APEXIGEN - COMBINATION OF INTRATUMORAL SOTIGALIMAB AND
SYSTEMIC
PEMBROLIZUMAB WAS WELL-TOLERATED AND DEMONSTRATED AN IMPROVED
CLINICAL RESPONSE RATE
* APEXIGEN - ACTIVATION OF ANTIGEN-PRESENTING CELLS
STIMULATED
BROAD INNATE AND ADAPTIVE ANTI-TUMOR RESPONSES IN LOCAL AS WELL
AS DISTANT TUMOR LESIONS
Source text for Eikon: ID:nGNX5lf5vg
Further company coverage: APGN.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Apexigen
See all newsBrief: Apexigen Inc - On August 15, Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard Transfer Of Listing From Nasdaq
Brief: Apexigen Says Phase 2 Data Evaluating Sotigalimab, Its CD40 Agonist Antibody, In Combination With Doxorubicin Marked Increases In Overall Survival Observed Across Soft Tissue Sarcoma Patients
Apexigen rises on buyout deal with Pyxis Oncology
Brief: Pyxis Oncology To Acquire Apexigen For Total Enterprise Value Of About $16 Million
Brief: Apexigen Inc Says On April 11, Co Received Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard From Nasdaq